JP2013507352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507352A5 JP2013507352A5 JP2012532683A JP2012532683A JP2013507352A5 JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5 JP 2012532683 A JP2012532683 A JP 2012532683A JP 2012532683 A JP2012532683 A JP 2012532683A JP 2013507352 A5 JP2013507352 A5 JP 2013507352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- composition according
- propargyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 21
- RUOKEQAAGRXIBM-UHFFFAOYSA-N n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2C(NCC#C)CCC2=C1 RUOKEQAAGRXIBM-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 206010047571 Visual impairment Diseases 0.000 claims description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical group CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 2
- JDBJJCWRXSVHOQ-UHFFFAOYSA-N methanesulfonic acid;n-prop-2-ynyl-2,3-dihydro-1h-inden-1-amine Chemical compound CS(O)(=O)=O.C1=CC=C2C(NCC#C)CCC2=C1 JDBJJCWRXSVHOQ-UHFFFAOYSA-N 0.000 claims description 2
- 230000001144 postural effect Effects 0.000 claims description 2
- 208000027765 speech disease Diseases 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 208000029257 vision disease Diseases 0.000 claims description 2
- 230000004393 visual impairment Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 13
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940001133 rasagiline 1 mg Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27867709P | 2009-10-09 | 2009-10-09 | |
| US61/278,677 | 2009-10-09 | ||
| PCT/IB2010/002852 WO2011042812A1 (en) | 2009-10-09 | 2010-10-08 | Use of rasagiline for the treatment of progressive supranuclear palsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013507352A JP2013507352A (ja) | 2013-03-04 |
| JP2013507352A5 true JP2013507352A5 (OSRAM) | 2013-11-28 |
Family
ID=43533485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012532683A Pending JP2013507352A (ja) | 2009-10-09 | 2010-10-08 | 進行性核上性麻痺の治療のためのラサギリンの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110130466A1 (OSRAM) |
| EP (1) | EP2485722A1 (OSRAM) |
| JP (1) | JP2013507352A (OSRAM) |
| AU (1) | AU2010304755A1 (OSRAM) |
| CA (1) | CA2777185A1 (OSRAM) |
| IL (1) | IL218948A0 (OSRAM) |
| WO (1) | WO2011042812A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| JP5701485B2 (ja) * | 2006-02-21 | 2015-04-15 | テバ ファーマシューティカル インダストリーズ リミティド | 多系統萎縮症の治療のためのラサギリンの使用 |
| MX2008012781A (es) | 2006-04-03 | 2008-10-14 | Teva Pharma | Uso de rasagilina para el tratamiento de sindrome de piernas inquietas. |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| PT2101569E (pt) * | 2006-12-14 | 2012-01-13 | Teva Pharma | Base de rasagilina sólida cristalina |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
| EP2234478A4 (en) * | 2008-01-11 | 2013-01-23 | Teva Pharma | RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE |
| US20100008983A1 (en) * | 2008-06-10 | 2010-01-14 | Muhammad Safadi | Rasagiline soft gelatin capsules |
| CN102065687A (zh) * | 2008-06-13 | 2011-05-18 | 泰华制药工业有限公司 | 雷沙吉兰用于改善帕金森氏症 |
| NZ589547A (en) * | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| DK2451771T3 (da) | 2009-07-09 | 2014-09-08 | Ratiopharm Gmbh | Salte af rasagilin og farmaceutiske fremstillingsmåder heraf |
| EP2515891A4 (en) * | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-N-propargyl-1-aminoindan |
| EP2603212A4 (en) | 2010-07-27 | 2014-01-08 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER |
| CA2806737A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| AU2012323349A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
| BR112014008552A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-metil-propargilaminoindano |
| CA2882072A1 (en) | 2012-08-17 | 2014-02-20 | Teva Pharmaceutical Industries Ltd. | Parenteral formulations of rasagiline |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101098685A (zh) * | 2004-11-24 | 2008-01-02 | 特瓦制药工业有限公司 | 雷沙吉兰经口崩解组合物 |
| DK2004204T3 (da) * | 2006-03-29 | 2013-01-07 | Velacor Therapeutics Pty Ltd | Behandling af neurodegenerative sygdomme med selenat |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| WO2009054544A1 (en) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for parkinson's disease and movement disorders |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| NZ589547A (en) * | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
| DE102008064061A1 (de) * | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| EP2603212A4 (en) * | 2010-07-27 | 2014-01-08 | Teva Pharma | USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER |
| CA2806737A1 (en) * | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| MX2013004598A (es) * | 2010-10-26 | 2013-07-17 | Teva Pharma | Rasagilina enriquesida con deuterio. |
| BR112014008552A2 (pt) * | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-metil-propargilaminoindano |
| AU2012323349A1 (en) * | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-formyl-propargyl-aminoindan |
| EA201490756A1 (ru) * | 2011-10-10 | 2014-09-30 | Тева Фармасьютикал Индастриз, Лтд. | Разагилина цитрамид |
-
2010
- 2010-10-08 EP EP10785198A patent/EP2485722A1/en not_active Withdrawn
- 2010-10-08 WO PCT/IB2010/002852 patent/WO2011042812A1/en not_active Ceased
- 2010-10-08 US US12/901,281 patent/US20110130466A1/en not_active Abandoned
- 2010-10-08 CA CA2777185A patent/CA2777185A1/en not_active Abandoned
- 2010-10-08 JP JP2012532683A patent/JP2013507352A/ja active Pending
- 2010-10-08 AU AU2010304755A patent/AU2010304755A1/en not_active Abandoned
-
2012
- 2012-03-29 IL IL218948A patent/IL218948A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507352A5 (OSRAM) | ||
| JP2013533287A5 (OSRAM) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2010013766A (es) | Rasagilina para modificacion de enfermedad de parkinson. | |
| EA201390827A1 (ru) | Применение лаквинимода для уменьшения утомляемости, улучшения функционального состояния и улучшения качества жизни пациентов с рассеянным склерозом | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| JP2011225596A5 (OSRAM) | ||
| JP2005506370A5 (OSRAM) | ||
| JP2016163571A5 (OSRAM) | ||
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2011516417A5 (OSRAM) | ||
| JP2014526503A5 (OSRAM) | ||
| JP2013541583A5 (OSRAM) | ||
| RU2013108258A (ru) | Применение разагилина для лечения обонятельной дисфункции | |
| JP2015155440A5 (OSRAM) | ||
| JP2011528333A5 (OSRAM) | ||
| JP2013509411A5 (OSRAM) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| PE20081106A1 (es) | Comprimidos pediatricos de capecitabina | |
| JP2016512817A5 (OSRAM) | ||
| JP2014508758A5 (OSRAM) | ||
| JP2016509601A5 (OSRAM) | ||
| JP2014524478A5 (OSRAM) | ||
| JP2008534503A5 (OSRAM) |